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Control of gene expression depends on a myriad of protein-DNA interactions, and the number of 
proteins involved just got larger. In this issue, Hu et al. (2009) identify hundreds of human proteins 
that bind to DNA, including many surprises such as the protein kinase ERK2 (MAPK1) that now 
appears to control gene expression directly.Cells respond to changes in their envi-
ronment with changes in gene expres-
sion. Signal transduction pathways make 
this happen as they transmit external 
cues from the cell surface to the nucleus. 
Transcription is regulated by the inter-
play of DNA cis-regulatory sequences 
and trans-acting factors. Although many 
classes of transcription factors have 
been well-studied, high-throughput 
approaches including chromatin immu-
noprecipitation (ChIP), microarrays, and 
deep sequencing have accelerated the 
discovery of novel protein-DNA interac-
tions across genomes creat-
ing new frontiers and chal-
lenges for understanding 
control of gene expression. 
Through a DNA-binding anal-
ysis of an array of more than 
4000 recombinant proteins, 
Hu et al. (2009) reporting in 
this issue now expand the set 
of human proteins known to 
bind to DNA directly, offer-
ing a fresh perspective on 
sequence-specific transcrip-
tion factors. Beyond the 
expected classes of tran-
scription factors, the authors 
discovered new DNA-protein 
interactions involving uncon-
ventional DNA-binding pro-
teins (uDBPs), such as the 
protein kinase ERK2 (MAPK1), 
that may alter gene expres-
sion directly by interacting 
with DNA.
Hu et al. (2009) come at the 
challenge of finding protein-
DNA interactions from the flip 
side of many DNA-centric studies look-
ing at transcription factor binding. They 
focus on the proteins, “printing” recom-
binant proteins onto arrays and prob-
ing for the DNA sequences that bind to 
them. They benchmark the approach by 
looking at known DNA-binding proteins. 
Consensus sequences were identified 
for more than 200 transcription fac-
tors, including canonical binding sites 
for uncharacterized, but suspected fac-
tors, such as members of the zf-C2H2 
subfamily. Surprisingly, the authors find 
that more than 300 uDBPs, including 
ERK2, bind to DNA in a sequence-spe-
cific manner. Through bioinformatics the 
authors predict that uDBPs account for 
more than 20% of the proteins encoded 
in the genome. Despite the abundance 
of uDBPs identified, even more are 
expected from protein classes that were 
excluded from the analysis (e.g., het-
erodimers, and proteins not known to be 
located in the nucleus).
Given the array analysis, it is conceiv-
able that the uDBPs may simply represent 
proteins with the adventitious ability to 
associate with DNA when taken out of their 
cellular context. Bolstering the 
case for the specificity of these 
interactions, the authors go 
on to characterize a subset of 
proteins in vitro and in vivo. 
They find, for instance, that the 
DNA consensus sequence G/
CAAAG/C interacts directly 
with recombinant ERK2 in vitro 
and confers ERK2-depen-
dent repression of luciferase 
reporter gene expression. 
Importantly, mutations in the 
protein sequence abrogate the 
interaction with DNA and tran-
scriptional repression does 
not depend on ERK2′s kinase 
activity. In search of an endog-
enous role for ERK2-mediated 
repression of transcription, Hu 
et al. (2009) knock down the 
protein and look at the conse-
quences for gene expression. 
Of 82 genes whose expression 
increases following siRNA-
mediated ERK2 knockdown, 
78 harbor one or more ERK2-
Figure 1. ERK2 Regulates Gene Expression
The protein kinase ERK2 regulates transcription indirectly by phosphorylation 
of transcriptional factors and cofactors. A new study (Hu et al., 2009) now 
shows that ERK2 not only binds to chromatin but also binds to DNA directly 
and can regulate expression of many different genes. In particular, ERK2 ap-
pears to repress expression of genes induced by interferon γ (IFNγ). (Inset) 
The crystal structure of ERK2 shows the insert region (green) that is required 
for binding to DNA. Mutations in residues shown in blue impair DNA binding. 
The tyrosine shown in red is required for binding to nuclear pore proteins and 
efficient entry into the nucleus. Mutation of this residue blocks nuclear entry 
and may thus prevent repression of genes regulated by IFNγ.462 Cell 139, October 30, 2009 ©2009 Elsevier Inc.
binding consensus motifs and roughly half 
are projected to bind to ERK2 based on 
ChIP analysis. The evidence is consistent 
with ERK2 acting directly as a transcrip-
tional repressor, but future studies will be 
needed to forge a mechanistic link between 
gene repression and ERK2 sequence-
specific binding to DNA. A fraction of gene 
expression changes may instead be medi-
ated through ERK2 substrates. ERK2 and 
its close relative the kinase ERK1 have 
nearly overlapping functions and both are 
expressed in the HeLa cells studied, sug-
gesting that ERK1 also may bind to DNA.
MAPKs are known to influence gene 
expression through several established 
mechanisms. For example, phospho-
rylation can modulate transcriptional 
components as in the case of the ter-
nary complex factor Elk-1, which, when 
phosphorylated by ERK2, boosts tran-
scription of genes like c-fos with serum 
response elements in their promoters 
(Gille et al., 1992). Activated ERK2, ERK1, 
as well as p38 MAPK can bind to chro-
matin (Lawrence et al., 2008; Pokholok 
et al., 2006), and the substrates of these 
kinases can directly phosphorylate his-
tones (Edmunds and Mahadevan, 2004). 
However, blocking kinase activity pre-
vents the transcriptional activity of these 
kinases, suggesting that the new direct 
transcriptional role described by Hu et 
al. is distinct.
To explore a biological context for 
ERK2-mediated gene repression in 
cells, Hu et al. (2009) studied a sub-
set of the ERK2-repressed genes that 
overlaps with a set of genes induced 
by interferon γ (IFNγ). They measured 
recruitment of ERK2 to the promoters 
of two genes, OAS1 and IRF9, involved 
in the IFNγ-induced immune response 
to viral infection. These promoters 
contain a conserved IFNγ-activated 
transcriptional DNA element (GATE) 
that is bound by the transcription fac-
tor C/EBP-β. An ERK2 binding consen-
sus sequence is embedded within the 
GATE element. The conclusions of the 
current study suggest that ERK2 and 
C/EBP-β may compete for binding to 
this element. Although some data sup-port this model, further work is needed 
to establish whether the proteins do in 
fact compete and if they do whether 
this interplay has functional conse-
quences. Upon activation by IFNγ, 
ERK2, ERK1, and RSK phosphorylate 
C/EBP-β, increasing its activity via 
enhanced binding to GATE and to the 
large transcriptional complex Mediator. 
This substrate-dependent mechanism 
could also account for the observed 
IFNγ-dependent induction of mRNAs 
from OAS1 and IRF9.
Hu et al. take advantage of structural 
information about ERK2 to design DNA-
binding defective mutant proteins. The 
key residues (K259 and R261) for DNA 
binding in ERK2 are in a region called 
the MAPK insert, and when either of 
these residues is mutated ERK2 does 
not bind to DNA to repress transcription 
(Figure 1). In the presence or absence of 
activating ligands, ERK2 and ERK1 bind 
to nuclear pore proteins enabling them 
to move in and out of the nucleus (Yazi-
cioglu et al., 2007), consistent with the 
fact that inactive ERK2 is in the nucleus 
and can repress transcription. The 
MAPK insert is also required for binding 
of ERK2 to nuclear pore proteins and 
hence for entry of the inactive protein 
into the nucleus. Mutation of some resi-
dues in the MAPK insert (e.g., tyrosine 
in Figure 1) or deletion of the insert itself 
impairs or prevents nuclear entry of the 
kinase (Yazicioglu et al., 2007). As a con-
sequence, ERK2 mutants that do not 
bind to DNA in vitro also may not be able 
to enter the nucleus in vivo as efficiently 
as wild-type ERK2. Thus, although data 
demonstrating binding of ERK2 to DNA 
in vitro are strong, parallel experiments 
in cells using loss-of-function mutants 
are not so easily interpreted. Interest-
ingly, the MAPK insert is found not only 
in MAPKs but also in cyclin-dependent 
kinases and GSK3. All three of these 
kinase families can bind to chromatin 
(Lawrence et al., 2008; Narayanan et 
al., 2005; Vincent et al., 2008), and thus 
the MAPK insert should be tested as a 
potential site for DNA binding in mem-
bers of these families.Cell 139,Until now no functions have been 
unequivocally attributed to inactive ERK2 
and ERK1. In contrast, Bardwell et al. 
(1998) found that the inactive yeast MAPK 
Kss1 represses transcription required for 
filamentous growth. In view of the work 
reported here, perhaps a repressive func-
tion is a common characteristic of inac-
tive MAPKs, which may bind to DNA with 
distinct sequence specificities. Perhaps 
foreshadowing the findings here, HipA, 
a bacterial kinase that is structurally 
similar to eukaryotic protein kinases, was 
recently shown to contact DNA directly 
in a complex with a transcriptional core-
pressor (Schumacher et al., 2009). We are 
left with the tantalizing idea that if kinases 
and other signaling molecules bind to the 
conserved regulatory sequences of tar-
get genes, then transcriptional regulation 
by signaling cascades may occur directly 
at the level of the genes themselves rather 
than only indirectly through regulation of 
trans-acting factors.
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